Answers are grounded in this paper and cite their sources.
This review examines the development and challenges of ATMPs in Slovenian transfusion medicine, suggesting potential improvements.
Background: Advanced therapy medicinal products (ATMPs) represent a transformative class of biological therapies, including gene therapies, somatic cell therapies, and tissue-engineered products, designed to address complex and often treatment-resistant conditions. This review provides a comprehensive overview of the evolving landscape of ATMP development and clinical implementation in Slovenian transfusion medicine. Summary: cell therapy for cardiomyopathies, dendritic-tumor cell hybrid vaccines for prostate cancer, and mesenchymal stromal cell applications in knee osteoarthritis, xerostomia, and kidney transplant rejection. While challenges persist, such as limited funding, small patient populations, and the need for regulatory adaptation, Slovenia possesses strong institutional capabilities and a geographical positioning that is conducive to regional collaboration. The SITM plays a central role in GMP-compliant manufacturing, quality control, and clinical support. Key Messages: The SITM plays a central national role in GMP-compliant manufacturing, quality control, and clinical support. To fully realize the potential of ATMPs, coordinated national strategies, targeted investment, and integration with European initiatives are essential. This review highlights Slovenia's progress, identifies key bottlenecks, and outlines opportunities for growth, emphasizing the role of transfusion medicine as a national platform for responsible and innovative ATMP development.
No takes yet. Share an insight, caveat, or question.
Švajger et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: